Clinical Trial Update: A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of RO7669330 in geographic atrophy due to age-related macu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• RO7669330

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Geographic Atrophy, Age-related Macular Degeneration | Phase 1 | Status: RECRUITING